Novo Nordisk A/S (NVO) 55.24 $NVO
Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 4.27 (+0.07), NVO: 55.24 (-0.11), DRRX: 1.86 (-0.02), BIOD: 0.41 (+0.01)
Novo Nordisk Falls 2.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 2:29PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $55.86 to a high of $56.30. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $56.32 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)
Lyfebulb Partners With Novo Nordisk A/S to Support Patient-Driven Innovations for People With Diabetes
Marketwire Canada - Tue Jul 19, 7:30AM CDT
NEW YORK, NY--(Marketwired - Jul 19, 2016) - Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease, announces a partnership with Novo Nordisk A/S, a global healthcare company driving change to defeat diabetes.
NVO: 55.24 (-0.11)
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia World Congress in Orlando
PR Newswire - Mon Jul 11, 11:00AM CDT
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia (WFH) World Congress in Orlando, FL, from July 24-28. The WFH Congress is the largest international meeting for the global bleeding disorders community.
NVO: 55.24 (-0.11)
Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S
PRWeb - Thu Jun 16, 9:09AM CDT
Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.
NVO: 55.24 (-0.11)
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 2:17PM CDT
Novo Nordisk (NVO) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
ABT: 44.89 (-0.06), NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77)
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 55.24 (-0.11)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 55.24 (-0.11)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 55.24 (-0.11)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 55.24 (-0.11)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 63.70 (-0.38), NVO: 55.24 (-0.11), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 55.24 (-0.11), LLY: 82.48 (-0.24)
Drug Manufacturers Stocks on Investors' Radar -- Synergy Pharma, Novo Nordisk, Biodel, and DURECT
PR Newswire - Thu Aug 04, 7:10AM CDT
The Drug Manufacturers segment is an intensive space that is driven by demand for medicines and related health-care products. Long-term industry outlook is positive with global sales projected to reach $1.4 trillion by 2019. Stock-Callers.com takes a look at the following companies and see what investors make of them: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Biodel Inc. (NASDAQ: BIOD), and DURECT Corp. (NASDAQ: DRRX). Learn more about these stocks by downloading their comprehensive and free reports at:
SGYP: 4.27 (+0.07), NVO: 55.24 (-0.11), DRRX: 1.86 (-0.02), BIOD: 0.41 (+0.01)
Novo Nordisk Falls 2.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 02, 2:29PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $55.86 to a high of $56.30. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $56.32 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)
Lyfebulb Partners With Novo Nordisk A/S to Support Patient-Driven Innovations for People With Diabetes
Marketwire Canada - Tue Jul 19, 7:30AM CDT
NEW YORK, NY--(Marketwired - Jul 19, 2016) - Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease, announces a partnership with Novo Nordisk A/S, a global healthcare company driving change to defeat diabetes.
NVO: 55.24 (-0.11)
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia World Congress in Orlando
PR Newswire - Mon Jul 11, 11:00AM CDT
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia (WFH) World Congress in Orlando, FL, from July 24-28. The WFH Congress is the largest international meeting for the global bleeding disorders community.
NVO: 55.24 (-0.11)
Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S
PRWeb - Thu Jun 16, 9:09AM CDT
Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.
NVO: 55.24 (-0.11)
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 2:17PM CDT
Novo Nordisk (NVO) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
ABT: 44.89 (-0.06), NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77)
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 55.24 (-0.11)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.24 (-0.11)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 55.24 (-0.11)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 55.24 (-0.11)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 55.24 (-0.11)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 63.70 (-0.38), NVO: 55.24 (-0.11), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 44.89 (-0.06), JNJ: 123.89 (-0.01), NVO: 55.24 (-0.11), SNY: 40.34 (-0.61)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 55.24 (-0.11)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.24 (-0.11), PFE: 35.27 (-0.02), BMY: 75.57 (+0.77), SNY: 40.34 (-0.61)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 55.24 (-0.11), LLY: 82.48 (-0.24)
